Stock Market Wire News Logo
Stock Market Wire News Logo
    • Login
    • Sign Up

Ad

Investor Relations

GILD Stock - Gilead Sciences Stock Trading


home / stock / gild

GILD GILD Quote GILD Short GILD News GILD Articles GILD Message Board

MWN AI Summary *

Gilead Sciences Inc. (NASDAQ: GILD) is a biopharmaceutical company headquartered in Foster City, California, known for its innovative therapies that treat life-threatening diseases, particularly in the areas of antiviral treatments, liver diseases, and oncology. Founded in 1987, Gilead has established itself as a leader in the development of treatments for HIV, hepatitis C, and COVID-19, significantly impacting public health worldwide.

A major catalyst for Gilead's growth has been its portfolio of antiviral drugs, particularly in the HIV market with products like Biktarvy and Descovy. The company also made headlines with its antiviral remdesivir, which received emergency use authorization in 2020 for the treatment of COVID-19. However, Gilead faced challenges as it navigated pricing pressures and increasing competition in the hepatitis C market, which has seen a decline in patient numbers and sales volumes.

Financially, Gilead has maintained a robust position, reporting steady revenue streams bolstered by its strong product lineup. The company continues to invest in research and development to expand its portfolio, focusing on both existing areas of strength and exploring new therapeutic avenues, including cell therapy and gene editing.

Looking ahead, Gilead aims to capitalize on growth opportunities in oncology, where it has made significant investments acquiring companies and platforms that enhance its capabilities. Additionally, Gilead's commitment to expanding access to its therapies through partnerships and affordable pricing strategies underscores its mission to address global health challenges.

Despite facing headwinds from the expiring patent protections on some key products and evolving market dynamics, Gilead Sciences remains a pivotal player in the biopharmaceutical industry, committed to innovation and improving patient outcomes globally.

MWN AI Analysis *

As of October 2023, Gilead Sciences Inc. (NASDAQ: GILD) presents a compelling investment opportunity within the biopharmaceutical sector, primarily driven by its robust pipeline, strategic acquisitions, and consistent revenue generation from core therapies. Investors looking to enter or expand their positions in GILD should consider several key factors.

Gilead has established itself as a leader in antiviral therapeutics, particularly in HIV and hepatitis C. The recent approval and uptake of its novel therapies, combined with ongoing clinical trials in oncology and inflammatory diseases, position the company favorably for sustained revenue growth. In particular, investors should note the promise of Gilead’s cell therapy programs and its efforts to innovate beyond traditional markets.

Moreover, Gilead's strategic acquisition of companies like Immunomedics and its investment in promising technologies such as CAR-T cell therapy bolster its competitive landscape. This positions Gilead to tap into lucrative oncology markets, which are projected to experience robust growth due to increasing global cancer incidences and advancements in treatment modalities.

Financially, Gilead maintains a solid balance sheet with significant cash reserves, providing flexibility for future investments and shareholder returns. Their historical commitment to returning capital through dividends is a noteworthy driver for income-focused investors, especially in an era where interest rates are adjusting.

However, it is essential to remain cognizant of market volatility influenced by regulatory decisions, competitive pressures, and potential pricing pressures from governmental policies on drug pricing. Gilead's shares may experience fluctuations based on results from pivotal clinical trials and market reactions to new launches.

Given the current landscape, investors should adopt a balanced approach—consider initiating or adding to positions in Gilead while closely monitoring upcoming trial data and market trends. This strategic positioning can capitalize on Gilead’s potential for growth while managing inherent risks in the biopharma sector.

* MWN AI Summary and Analysis is based on asking OpenAI to summarize and analyze the company and stock symbol.


About | Gilead Sciences Inc. (NASDAQ:GILD)

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite acquisition and pending Forty-Seven acquisition boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Quote | Gilead Sciences Inc. (NASDAQ:GILD)

Last:$114.54
Change Percent: 0.15%
Open:$113.07
Close:$114.54
High:$114.87
Low:$112.8301
Volume:6,092,400
Last Trade Date Time:07/10/2025 03:40:44 pm

News | Gilead Sciences Inc. (NASDAQ:GILD)

  • Arcus Biosciences' cancer drug gets orphan drug status

    2025-07-10 10:24:43 ET More on Arcus Biosciences, Gilead Sciences Kymera Shrugs Off Sanofi Bust With Gilead Deal--But There Are Caveats Gilead Sciences: Strong Buy On Pipeline Momentum And Cost Discipline Gilead Sciences, Inc. (GILD) Presents at Goldman Sachs 46th An...

    • July 10, 2025 10:24:43 am

    • |
    • SeekingAlpha
    • |
      • GILD Stock
      • GILD Quote
      • GILD Short
      • GILD News
      • GILD Articles
      • GILD Message Board
  • FDA publishes more than 200 rejection letters in a bid to improve transparency

    2025-07-10 09:35:40 ET More on Merck, Pfizer, etc. Bristol Myers Squibb: Hidden Facts Blur The Strength Of The Company Merck Buys Verona Pharma: A Good Deal, But M&A Spree Must Continue Johnson & Johnson: What To Expect From The Upcoming Q2 Earnings? ...

    • July 10, 2025 09:35:40 am

    • |
    • SeekingAlpha
    • |
      • GILD Stock
      • GILD Quote
      • GILD Short
      • GILD News
      • GILD Articles
      • GILD Message Board

Message Board Posts | Gilead Sciences Inc. (NASDAQ:GILD)

Subject By Source When
Why is an oral prodrug of Remdesivir anything DewDiligence investorshub 04/06/2023 1:08:29 AM
Obeldesivir (an oral prodrug of remdesivir) https://news.yahoo.com/gilead-detail jondoeuk investorshub 04/05/2023 10:34:08 PM
Kite just released ZUMA-7 results for 2L https://www.businesswire.com/news/home/ jondoeuk investorshub 03/21/2023 8:18:16 PM
Christmas sell off over, last day to lock fink investorshub 12/29/2022 6:13:36 PM
It wants $90. fink investorshub 12/09/2022 3:32:27 PM

MWN AI FAQ **

What recent developments or innovations have been introduced by Gilead Sciences Inc. (NASDAQ: GILD) in their antiviral therapies that could impact market share?

Gilead Sciences has introduced advancements in its antiviral therapies, including new formulations and delivery methods for products like Biktarvy and Veklury, enhancing efficacy and accessibility, which could potentially increase their market share in the antiviral sector.

How has Gilead Sciences Inc. GILD's pipeline for oncology products progressed, and what does it mean for their growth potential?

Gilead Sciences Inc.'s oncology pipeline has seen promising advancements, particularly with its CAR-T cell therapies and immune-oncology treatments, which significantly enhance its growth potential by addressing unmet needs in cancer care and expanding market opportunities.

What is the current financial outlook for Gilead Sciences Inc. (NASDAQ: GILD) considering recent earnings reports and market trends?

As of October 2023, Gilead Sciences Inc. exhibits a cautiously optimistic financial outlook, bolstered by recent earnings beats and strong demand for its antiviral products, although concerns over pipeline developments and market competition persist.

How is Gilead Sciences Inc. GILD addressing potential challenges from competition in the pharmaceutical sector, particularly in HIV and hepatitis treatments?

Gilead Sciences Inc. is addressing competition challenges in the pharmaceutical sector, particularly in HIV and hepatitis treatments, by focusing on research and development, expanding its pipeline of innovative therapies, and strategic collaborations to enhance its market position.

** MWN AI Questions are based on asking OpenAI to ask and answer four questions about the company and stock symbol.

Stock Information

Get GILD Alerts

News, Short Squeeze, Breakout and More Instantly...

Gilead Sciences Inc. Company Name:

GILD Stock Symbol:

NASDAQ Market:

0.15% G/L:

$114.54 Last:

6,092,400 Volume:

$113.07 Open:

$114.54 Close:

Gilead Sciences Inc. Website:

Gilead Sciences Inc. Logo

Ad

Investor Relations
RECENT GILD NEWS
  • GILD - Gilead Finalizes Agreement With the Global Fund to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries

    – Strategic Partnership Agreement is Part of Gilead’s Commitment to Provide Lenacapavir at No Profit in High-Incidence, Resource-Limited Countries Until Licensed Generics Can Fully Meet Demand – Gilead Sciences, Inc. (Nasdaq: GILD) today announced a strategic pa...

  • GILD - Gilead Sciences: A Mixed Bag of Opportunities and Risks

    2025-07-01 19:00:00 ET Explore the exciting world of Gilead Sciences (NASDAQ: GILD) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities! *Stock prices used ...

  • GILD - Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders

    Gilead Sciences, Inc. (NASDAQ: GILD) and Kymera Therapeutics, Inc. (NASDAQ: KYMR), today announced that they have entered into an exclusive option and license agreement to accelerate the development and commercialization of a novel molecular glue degrader (MGD) program targeting cyclin-dependent ...

  • Research
  • Stock Search
  • News Releases
  • Articles
  • Topics
  • Message Boards
  • Trending Stocks
  • Trending Feed
  • Trending Alerts
  • Watchlist
  • Short Information
  • Stock Wall
  • Link Twitter
  • Sign Up
  • Login
  • Contact

Link your X Account

Link your X Account to Market Wire News

When you linking your X Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your X account.

Be alerted of any news about your stocks and see what other stocks are trending.



Connect with Us

Join our Telegram Alerts Channel

Telegram

Join our Discord

Discord

Get GILD Alerts

Get GILD Alerts

News, Short Squeeze, Breakout and More Instantly...

Sign up or login to continue

Sign up or login to continue.


Forgot password?




Mobile Number Subscribers

Market Wire News provides notifications to customers about updates, service, reminders, or products. Current and new customers of Market Wire News will enter their mobile numbers on a web opt-in form https://marketwirenews.com. Supported Carriers are as follows Alltel, AT&T, Cincinnati Bell, Dobson Cellular Systems, Inter Op, MetroPCS®, Nextel Communications, Sprint PCS, T-Mobile®, U.S. Cellular®, Verizon Wireless, and Virgin Mobile U.S. T-Mobile® is not liable for delayed or undelivered messages. There are no premium charges for joining Market Wire News service. Message and data rates may apply. Subscribers to Market Wire News service may receive up to 500 per month.

How to Opt Out

To opt-out of the Market Wire News program, send or text STOP, END, QUIT, CANCEL or UNSUBSCRIBE to (844) 931-3999. An unsubscribe message will be sent to your number confirming the cancellation, but no more messages will be sent after that one.

Mobile Support

For support or information about a Market Wire News, send or text HELP to (844) 931-3999. Optionally, you may email support@marketwirenews.com.


Disclaimer

This electronic content is for the purposes of solicitation subscriptions for Market Wire News. Market Wire News expects to generate new advertisement revenue resulting from the distribution of this electronic content. The amount of which is unknown at this time. Market Wire News is not a registered investment adviser or broker-dealer. This electronic content does not provide a professional analysis of a any stock financial position. any stock's financial position and all other information regarding the featured Company should be verified directly with any stock. This electronic content is provided as an information service only, and any statements and opinions in this electronic content should not be construed as an offer or solicitation to buy or sell any security. Market Wire News accepts no liability for any loss arising from an investor's reliance on or use of this electronic content. An investment in any company is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. Market Wire News does not own, buy, sell or plans to own, buy, sell, and of any stock's shares. This electronic content contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Please read our full disclaimer for compensation and more detailed information.

Advertise

Brand your company, advertise your products or services with our ad programs.

Advertise

Research

Stock Search

News Releases

Articles

Message Boards

Trending Stocks

Short Information

Stock Wall

Members

Log In

Sign Up

Stay Connected

| X

| Facebook

| BlueSky

| LinkedIn

| Telegram

| Discord


Contact

Privacy

Terms of Service

Disclaimer

© 2025 Market Wire News 1